Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis
Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis
复制标题
DOI：
10.1016/j.tjog.2021.03.016
复制
发表时间：
2021-05-06
影响因子：
2.1
通讯作者：
Wang, Fang
中科院分区：
文献类型：
--
作者：
Yang, Xin;Cao, Jin-Long;Wang, Fang
目的：钙激活氯离子通道2（CLCA 2）与一些常见恶性肿瘤的侵袭、转移及预后密切相关。本研究旨在通过生物信息学分析探讨CLCA 2在宫颈鳞状细胞癌（CESC）中的作用，材料和方法：分别从GEO（Gene Expression Omnibus）数据库和TCGA（The Cancer Genome Atlas）数据库中获取CLCA 2的mRNA序列和相应的临床资料。采用单因素方差分析法分析CLCA 2 mRNA在正常宫颈组织、宫颈上皮内瘤变（CIN）组织和CESC组织中的表达差异，并分析其临床病理特征。采用基因表达谱交互分析（Gene Expression Profiling Interactive Analysis，GEPIA）方法分析CLCA 2与无病生存期（Disease-Free Survival，DFS）、总生存期（Overall Survival，OS）的关系。基因集富集分析（GSEA）被用来探索相关的信号通路。结果：CLCA 2在CESC组织中的表达明显低于正常组织和CIN组织（P < 0.05）;肥胖组CLCA 2表达水平低于正常体重组（P < 0.05）。而在不同T分期、淋巴结转移、FIGO分期的CC中，CLCA 2的表达水平差异无统计学意义（P > 0.05）。生存分析显示，对于DFS，CLCA 2高表达的CESC比低表达的CESC具有更好的生存率（P < 0.05）。但对于操作系统来说，没有什么区别。GSEA结果显示，CLCA 2高表达表型中有4条信号通路表现出显著的差异富集，包括P53信号通路、ERBB信号通路、NOTCH信号通路和泛素介导的蛋白水解。TIMER结果显示CLCA 2的表达与B细胞、巨噬细胞和树突状细胞浸润呈显著负相关。结论：CLCA 2的表达可能是CESC患者的一个潜在的预后指标。(c)2021台湾妇产科学会Taiwan Association of Obstetrics & Gynecology Elsevier B. V.的出版服务。这是CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Objective: Calcium-activated chloride channel 2 (CLCA2) is closely related to the invasion, metastasis, and prognosis of some common malignant tumors. The present study aimed to evaluate the role of CLCA2 in cervical squamous cell carcinoma (CESC) using bioinformatics analysis.Materials and methods: The mRNA sequencing data and the corresponding clinical data were obtained from Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database respectively. Then univariate analysis of variance was used to analyze the differential mRNA expression of CLCA2 between normal, cervical Intraepithelial neoplasia (CIN), and CESC tissues and clinicopatho-logical characteristics. The Gene Expression Profiling Interactive Analysis (GEPIA) was used to assess the association between CLCA2 and Disease-Free Survival (DFS), overall survival (OS). The Gene Set Enrichment Analysis (GSEA) was used to explore the associated signaling pathways. The Tumor Immune Estimation Resource (TIMER) was used to predict the potential biological roles of CLCA2 in tumor -immune of CESC.Results: CLCA2 expression was significantly decreased in CESC tissues compared with normal and CIN tissues (P < 0.05). Meanwhile, obese patients had lower levels of CLCA2 expression than normal-weight CESC patients (P < 0.05). However, there was no significant difference in the expression level of CLCA2 in patients with different T stage, lymph node status, metastasis, and FIGO stage in CC(P > 0.05). The survival analysis indicated that for DFS, CESC with high CLCA2 expression was associated with better prognoses compared with those with low expression levels (P < 0.05). But for the OS, there was no difference. GSEA revealed that 4 pathways exhibited significant differential enrichment in the CLCA2 high-expression phenotype, including the P53 signaling pathway, the ERBB signaling pathway, the NOTCH signaling pathway, and the ubiquitin-mediated proteolysis. The TIMER reveals the expression of CLCA2 showed a significant inverse association with the number of B cells, Macrophage cells, and Dendritic Cell infiltration.Conclusion: The present study indicates that CLCA2 expression may be a potential prognostic marker for patients with CESC.(c) 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).